Immune Therapeutics (OTCMKTS:IMUN) Shares Down 8.6%
Immune Therapeutics Inc (OTCMKTS:IMUN) shares traded down 8.6% on Friday . The stock traded as low as $0.01 and last traded at $0.01, 75,750 shares traded hands during trading. A decline of 80% from the average session volume of 372,763 shares. The stock had previously closed at $0.01.
The company’s 50-day simple moving average is $0.01 and its two-hundred day simple moving average is $0.01.
Immune Therapeutics (OTCMKTS:IMUN) last announced its quarterly earnings results on Tuesday, November 19th. The company reported ($2.07) earnings per share for the quarter.
Immune Therapeutics, Inc, together with its subsidiaries, focuses on the development and commercialization of therapeutic treatments for cancer, human immunodeficiency virus (HIV)/AIDS, and autoimmune and immune disorders in the United States and internationally. It develops methionine enkephalin IRT-101, a small synthetic pentapeptide; and low-dose naltrexone IRT-103, an opioid receptor antagonist that stimulates and/or regulates the immune system to treat a range of autoimmune diseases, including multiple sclerosis; immune disorders, such as Crohn's disease and cancer; and viral infections comprising HIV/AIDS.
Recommended Story: Liquidity
Receive News & Ratings for Immune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.